Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Levena Biopharma is a specialized biotechnology company and Contract Development and Manufacturing Organization (CDMO) focused on the development of Antibody-Drug Conjugates (ADCs). As a subsidiary of Sorrento Therapeutics, the company provides comprehensive services including site-specific conjugation technology, linker-payload synthesis, and GMP manufacturing of ADC drug substances. Their proprietary platforms, such as K-lock and C-lock, enable the production of homogeneous ADCs with improved therapeutic indexes compared to traditional random conjugation methods. Levena operates state-of-the-art facilities in Suzhou, China, and San Diego, California, supporting global biopharmaceutical partners from early-stage discovery through clinical development. The company is recognized for its integrated approach, managing both the complex chemistry of payloads and the biological requirements of antibody production.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Levena Suzhou Biopharma.